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Background
A heterologous prime-boost vaccination strategy using
GVAX pancreas vaccine and CRS-207 is showing pro-
mise in patients with pancreatic adenocarcinoma (PDA)
(Le, JCO 2015). Furthermore, blockade of the immune
checkpoint programmed death-1 (PD-1) is active in
some cancers. Combinatorial strategies aimed at priming
tumor antigen-specific T cells while simultaneously block-
ing negative checkpoints may be necessary to improve
outcomes in PDA. GVAX is composed of allogeneic pan-
creatic cancer cells modified to express GM-CSF and
induces a broad response against multiple tumor antigens.
GVAX is given with low-dose cyclophosphamide (CY) to
inhibit regulatory T cells. CRS-207 is live-attenuated Lis-
teria monocytogenes engineered to express the tumor-asso-
ciated antigen mesothelin. CRS-207 boosts responses
against mesothelin and is unique in its capacity to stimu-
late both innate and adaptive immunity by activating
T cells and NK cells. Nivolumab is an antibody against
PD-1.
Methods
This is a Phase II study comparing CY/GVAX and CRS-
207 with or without nivolumab in subjects with PDA who
failed only one chemotherapy regimen for metastatic dis-
ease. Subjects are randomized in a 1:1 ratio to receive
either 2 doses of CY/nivolumab/GVAX and 4 doses of
nivolumab/CRS-207 (Arm A) or 2 doses of CY/GVAX
and 4 doses of CRS-207 (Arm B). The primary objective is
to compare OS between Arms A and B. Secondary/
exploratory objectives include: assessment of safety and
clinical responses (tumor assessments and CA19-9 levels)
and correlation of Lm- and mesothelin-specific T cell and
other immunological responses with OS, progression-free
survival and best overall response.
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